References

Individualized antiretroviral therapeutic approaches: less can be more

10.1097/qad.0000000000001476 · 2017 · External reference

Two-drug regimens for HIV treatment

10.1016/s2352-3018(22)00249-1 · 2022 · External reference

Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO study

10.1093/cid/ciz1243 · 2020 · External reference

Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial

10.1093/cid/ciac130 · 2023 · External reference

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

10.1016/s0140-6736(17)33095-7 · 2018 · External reference

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the phase II ANRS 163 ETRAL study

10.1093/jac/dkz224 · 2019 · External reference

Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12 h) regimen

10.1093/jac/dkaa423 · 2021 · External reference

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

10.1016/s0140-6736(09)60918-1 · 2009 · External reference

Raltegravir with optimized background therapy for resistant HIV-1 infection

10.1056/nejmoa0708975 · 2008 · External reference

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1–infected patients: 156-week results from STARTMRK

10.1093/cid/cir510 · 2011 · External reference

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

10.1016/s0140-6736(12)61853-4 · 2013 · External reference

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

10.1016/s0140-6736(09)62041-9 · 2010 · External reference

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

10.1097/qad.0b013e32833a608a · 2010 · External reference

Long-term safety from the raltegravir clinical development program

10.2174/157016211794582650 · 2011 · External reference

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

10.1016/s2352-3018(19)30336-4 · 2020 · External reference

Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial

10.1093/cid/ciy540 · 2019 · External reference

Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial

10.1097/qai.0000000000002056 · 2019 · External reference

In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways

10.1128/aac.04201-14 · 2015 · External reference

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

10.1016/s2352-3018(17)30128-5 · 2017 · External reference

Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry

10.1002/bmc.865 · 2007 · External reference

Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects

10.3851/imp2920 · 2015 · External reference

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

10.1097/qai.0b013e31802b4956 · 2006 · External reference

Polypharmacy in HIV: recent insights and future directions

10.1097/coh.0000000000000608 · 2020 · External reference

Clinical pharmacokinetics of the novel HIV-1 non-nucleoside reverse transcriptase inhibitor doravirine: an assessment of the effect of patient characteristics and drug-drug interactions

10.1007/s40261-020-00934-2 · 2020 · External reference

Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of doravirine

10.1007/s40262-019-00806-9 · 2019 · External reference

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms

10.1038/clpt.2009.12 · 2009 · External reference

Real-life use of doravirine in treatment-experienced people living with HIV: a multicenter Italian study

10.1097/md.0000000000029855 · 2022 · External reference

Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations

10.1111/hiv.13615 · 2024 · External reference

Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study

10.1093/jac/dkad185 · 2023 · External reference

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial

10.1016/s0140-6736(25)01948-8 · 2026 · External reference

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

10.1016/s0140-6736(25)01945-2 · 2026 · External reference

In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations

10.1093/jac/dkaa401 · 2021 · External reference

Review of doravirine resistance patterns identified in participants during clinical development

10.1097/qai.0000000000002496 · 2020 · External reference

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance

10.1186/s12981-023-00503-5 · 2023 · External reference

Metabolic complications associated with use of integrase strand transfer inhibitors (InSTI) for the treatment of HIV-1 infection: focus on weight changes, lipids, glucose and bone metabolism

10.1007/s11904-024-00708-x · 2024 · External reference

Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men

10.1093/cid/cit252 · 2013 · External reference

HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens

10.1093/cid/ciu187 · 2014 · External reference

Contemporary antiretroviral pharmacology in the male genital tract: implications for HIV treatment and prevention

10.1128/aac.01401-25 · 2026 · External reference